Elevation Oncology, Inc. announced that Shawn M. Leland, PharmD, RPh, has resigned from his role as chief executive officer, effective immediately. Mr. Ferra will remain as the Company's chief financial officer, and lead Elevation Oncology along with Valerie Malyvanh Jansen, MD, PhD, Chief Medical Officer and David Dornan, PhD, Chief Scientific Officer. Effective as of January 5, 2023 (the Separation Date), the Board appointed Joseph J. Ferra, Jr., the Company's Chief Financial Officer, to succeed Dr. Leland as Interim Chief Executive Officer.

Mr. Ferra will also remain Chief Financial Officer while serving as Interim Chief Executive Officer. Mr. Ferra, age 47, has served as the Company's Chief Financial Officer since June 2021. Mr. Ferra joined the Company from Syros Pharmaceuticals, Inc., where he served as Chief Financial Officer from March 2018 to June 2021.

Prior to Syros, Mr. Ferra was employed at JMP Securities LLC, where he served as Managing Director from March 2014 to March 2018, Head of East Coast Healthcare Banking from March 2015 to March 2017 and Co-Head of Healthcare Investment Banking from March 2017 to March 2018. Previously, he was employed by UBS Investment Bank from September 2009 to March 2014 serving, most recently, as Executive Director of global healthcare investment banking. Mr. Ferra received a B.S. in chemistry with distinction from Purdue University and an M.B.A. from The Stephen M. Ross School of Business at the University of Michigan.

From the Separation Date until January 5, 2024 (the Advisory End Date), Dr. Leland will continue as an advisor of the Company. The Company will enter into an advisory agreement (the Advisory Agreement) with Dr. Leland, pursuant to which Dr. Leland has agreed to serve as a non-employee advisor to the Company until the Advisory End Date.